141 related articles for article (PubMed ID: 2557953)
1. Medullary carcinoma of the thyroid: management of persistent hypercalcitonaemia utilizing [99mTc] (v) dimercaptosuccinic acid scintigraphy.
Udelsman R; Mojiminiyi OA; Soper ND; Buley ID; Shepstone BJ; Dudley NE
Br J Surg; 1989 Dec; 76(12):1278-81. PubMed ID: 2557953
[TBL] [Abstract][Full Text] [Related]
2. Pentavalent Tc-99m DMSA scintigraphy. Prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid.
Mojiminiyi OA; Udelsman R; Soper ND; Shepstone BJ; Dudley NE
Clin Nucl Med; 1991 Apr; 16(4):259-62. PubMed ID: 1646098
[TBL] [Abstract][Full Text] [Related]
3. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
[TBL] [Abstract][Full Text] [Related]
4. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
Verga U; Muratori F; Di Sacco G; Banfi F; Libroia A
Henry Ford Hosp Med J; 1989; 37(3-4):175-7. PubMed ID: 2576958
[TBL] [Abstract][Full Text] [Related]
5. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
[TBL] [Abstract][Full Text] [Related]
6. Technetium 99m pentavalent dimercaptosuccinic acid and thallium 201 in detecting recurrent medullary carcinoma of the thyroid.
Bigsby RJ; Lepp EK; Litwin DE; Wilkinson AA; Matte GG
Can J Surg; 1992 Aug; 35(4):388-92. PubMed ID: 1323381
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid.
Ugur O; Kostakğlu L; Güler N; Caner B; Uysal U; Elahi N; Haliloğlu M; Yüksel D; Aras T; Bayhan H; Bekdik C
Eur J Nucl Med; 1996 Oct; 23(10):1367-71. PubMed ID: 8781142
[TBL] [Abstract][Full Text] [Related]
8. The use of 99mTc(V)DMSA as imaging for the medullary thyroid carcinoma (MTC).
Guerra U; Pizzocaro C; Terzi A; Giubbini R; Bestagno M
J Nucl Med Allied Sci; 1988; 32(4):242-7. PubMed ID: 2852709
[No Abstract] [Full Text] [Related]
9. Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP--an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid.
Clarke SE; Lazarus CR; Wraight P; Sampson C; Maisey MN
J Nucl Med; 1988 Jan; 29(1):33-8. PubMed ID: 2826723
[TBL] [Abstract][Full Text] [Related]
10. A new imaging agent for medullary carcinoma of the thyroid.
Ohta H; Yamamoto K; Endo K; Mori T; Hamanaka D; Shimazu A; Ikekubo K; Makimoto K; Iida Y; Konishi J
J Nucl Med; 1984 Mar; 25(3):323-5. PubMed ID: 6321700
[TBL] [Abstract][Full Text] [Related]
11. Pentavalent Tc-99m DMSA accumulation in a medullary carcinoma of the thyroid.
Hirano T; Otake H; Watanabe N; Oriuchi N; Fukuda T; Endo K
Clin Nucl Med; 1997 May; 22(5):339-40. PubMed ID: 9152545
[No Abstract] [Full Text] [Related]
12. Tc-99m-(V)-DMSA: the new sensitive and specific radiopharmaceutical for imaging metastases of medullary thyroid carcinomas?
Becker W; Börner W; Reiners C
Horm Metab Res Suppl; 1989; 21():38-42. PubMed ID: 2553574
[TBL] [Abstract][Full Text] [Related]
13. The role of technetium-99m pentavalent DMSA in the management of patients with medullary carcinoma of the thyroid.
Clarke SE; Lazarus C; Mistry R; Maisey MN
Br J Radiol; 1987 Nov; 60(719):1089-92. PubMed ID: 2825895
[TBL] [Abstract][Full Text] [Related]
14. Experience in imaging medullary thyroid carcinoma using 99mTc (V) dimercaptosuccinic acid (DMSA).
Clarke S; Lazarus C; Maisey M
Henry Ford Hosp Med J; 1989; 37(3-4):167-8. PubMed ID: 2576956
[TBL] [Abstract][Full Text] [Related]
15. 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma.
Berná L; Cabezas R; Mora J; Torres G; Estorch M; Carrió I
J Endocrinol; 1995 Feb; 144(2):339-45. PubMed ID: 7706986
[TBL] [Abstract][Full Text] [Related]
16. Technetium-99m-pentavalent dimercaptosuccinic acid uptake in Hurthle cell tumor of the thyroid.
Vergara E; Lastoria S; Varrella P; Lapenta L; Salvatore M
J Nucl Biol Med (1991); 1993 Jun; 37(2):65-8. PubMed ID: 8396979
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of 99mTc(V)-dimercapto succinic acid (DMSA) for imaging medullary carcinoma of thyroid and its metastasis.
Patel MC; Patel RB; Ramanathan P; Ramamoorthy N; Krishna BA; Sharma SM
Eur J Nucl Med; 1988; 13(10):507-10. PubMed ID: 2836203
[TBL] [Abstract][Full Text] [Related]
18. Preparation and clinical evaluation of technetium-99m dimercaptosuccinic acid for tumour scintigraphy.
Hirano T; Tomiyoshi K; Zhang YJ; Ishida T; Inoue T; Endo K
Eur J Nucl Med; 1994 Jan; 21(1):82-5. PubMed ID: 8088289
[TBL] [Abstract][Full Text] [Related]
19. [Medullary carcinoma of the thyroid and 99mTc(V)-DMSA scintigraphy. Clinical results with a new radiopharmaceutical].
Kujat C; Neidl K; Müller-Leisse C
Rofo; 1990 Nov; 153(5):495-500. PubMed ID: 2173051
[TBL] [Abstract][Full Text] [Related]
20. Imaging with pentavalent [99mTc]DMSA in patients with medullary cancer of the thyroid.
Hilditch TE; Murray T; Connell JM; McLellan AR; Reed NS
J Nucl Med; 1988 Oct; 29(10):1746-7. PubMed ID: 2845025
[No Abstract] [Full Text] [Related]
[Next] [New Search]
